BRAF and melanoma: In addition, ITGAV-positive cancer cells demonstrated chemoresistance to 5-fluorouracil (5-FU) and oxaliplatin.36 This observation was in line with the current results showing increased ITGAV levels in viable BRAF-positive melanoma cells after vemurafenib treatment.